* Akili Inc reported a quarterly adjusted loss of 12 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of -17 cents. The lone analyst forecast for the quarter was for a loss of 14 cents per share.
* Revenue rose 238.9% to $383.00 thousand from a year ago; analysts expected $794.00 thousand.
* Akili Inc's reported EPS for the quarter was a loss of 12 cents.
* The company reported a quarterly loss of $9.76 million.
* Akili Inc shares had risen by 51.4% this quarter and lost 10.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 17.6% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced medical equipment & technology peer group is "hold."
Wall Street's median 12-month price target for Akili Inc is $0.65 This summary was machine generated from LSEG data May 14 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.14 -0.12 Beat
Dec. 31 2023 -0.21
Sep. 30 2023 -0.19 -0.18 Beat
Jun. 30 2023 -0.20 -0.16 Beat
Comments